相关实验视频
Updated: Jul 20, 2025

08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
21.1K
强化治疗可以改善新诊断的晚期外节NK/T细胞淋巴瘤的长期存活率:一个多机构,现实世界的研究
Yu-Ce Wei1, Fei Qi2, Bao-Min Zheng3
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
International journal of cancer
|August 4, 2023
概括
晚期突节自然杀手/T细胞淋巴瘤 (ENKTL) 的存活率通过化疗加放射治疗和干细胞移植得到改善. 基于gemcitabine的治疗方案和基达胺维护疗法在ENKTL患者中显示出更好的结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 外节自然杀手/T细胞淋巴瘤 (ENKTL) 是一种侵袭性的非霍奇金淋巴瘤.
- 晚期ENKTL的治疗和预后仍然具有挑战性.
研究的目的:
- 调查晚期ENKTL.患者的治疗策略和生存结果.
- 评估不同化疗方案,放射治疗和干细胞移植的疗效.
主要方法:
- 对195名新诊断的III/IV期ENKTL患者的回顾性分析.
- 基于治疗方式的总生存 (OS) 和无进展生存 (PFS) 的比较.
- 多变量分析以确定预后因素.
主要成果:
- 平均寿命为19.43个月,5年寿命为35.1%.
- 化疗加放射治疗 (CT+RT) 和造血干细胞移植 (HSCT) 显著改善了OS.
- 基于格姆西塔的治疗方案和基达胺维护疗法对PFS和OS显示出潜在的益处.
结论:
- 强化一线治疗,包括CT (特别是Gem + Aspa疗法),RT,HSCT和奇达胺维护疗法,可以改善晚期ENKTL的长期存活率.
- 需要进一步的前性研究来证实基达米德维持治疗的作用.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Cytotoxic T Cells-mediated Immune Response
971
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
971
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

